Biogen to buy Syntonix in $120M deal

Biogen Idec has moved to beef up its pipeline by acquiring Syntonix Pharmaceuticals for $40 million down and up to $80 million in milestone payments. Biogen Idec says it will maintain Syntonix's 25,000-square-foot facility in Waltham, MA. Biogen gains a lead product for hemophilia B and technology for developing inhalable treatments.

- here's release on Biogen's latest deal